Singlepoint Healthcare accelerates market expansion with acquisition of national infusion services provider Healix

Singlepoint Healthcare has acquired Healix, an outpatient infusion management provider operating over 220 centers across the United States, expanding its clinical network for complex inflammatory disease treatments.

A significant consolidation has occurred in the specialized healthcare delivery sector according to official corporate disclosures. Singlepoint Healthcare has finalized the acquisition of Healix, a prominent domestic provider that manages more than 220 ambulatory and physician-owned infusion centers across the United States.

Singlepoint Healthcare is an integrated clinical services platform focused on multi-specialty medical care and advanced therapeutic administration for chronic inflammatory conditions. This transaction represents Singlepoint's third strategic acquisition within a twelve-month period, building on its previous acquisitions of IV Solutions and The Boster Center for Multiple Sclerosis.

The integration of Healix's established clinical footprint directly addresses the logistical challenges of decentralized patient care by streamlining the distribution of specialized biologic therapies. This development signals a broader shift in the healthcare services industry toward consolidated outpatient infrastructure, directly impacting medical logistics providers, specialty pharmaceutical distributors, and private equity investors in the clinical space.

For institutional stakeholders, the expansion underscores a growing commercial emphasis on accessible ambulatory care models designed to reduce treatment delays and optimize operational efficiencies for complex therapeutic regimens.